[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cryptococcal-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cryptococcal-infection":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":4,"leadSponsor":43,"locationsCount":46},"100054401","fungal-infection-susceptibility-100054401",false,"NCT00001352","Fungal Infection Susceptibility","Cryptococcosis in Previously Healthy Adults","* INCLUSION CRITERIA:\n\nPatients\n\nPatients must:\n\n1. Have cryptococcosis as determined by information collected from their medical records, telephone interviews, or from a referring physician:\n\n   * histopathology showing cryptococci; or\n   * culture of C. neoformans or C. gattii\n   * a positive cryptococcal antigen in the serum and\u002For CSF, together with CSF cell count and chemistry consistent with cryptococcal meningitis.\n2. Be over the age of 18 years old.\n3. Have a primary physician outside of the NIH.\n4. Agree to undergo genetic testing that will include WES and high density SNP arrays as appropriate for possible WES linkage studies.\n5. Allow samples to be stored for future research.\n6. Pregnant patients will not be excluded. However, research procedures greater than minimal risk including bone marrow biopsy and apheresis would not be performed on pregnant subjects. Otherwise, pregnant patients with cryptococcus would be treated with as per standard of care, minimizing teratogenic potential of drugs and ionizing radiation whenever possible.\n\nBlood Relatives of Patients\n\nBlood relatives must:\n\n1. Be a genetic relative of a patient enrolled in this study\n2. Be over the age of 18 years old\n3. Agree to undergo genetic testing that may include WES and high density SNP analysis\n4. Allow samples to be stored for future research\n\nHealthy Volunteers\n\nHealthy volunteers must:\n\n1. Be between the ages of 18 and 70 years old\n2. Allow samples to be stored for future research\n\nEXCLUSION CRITERIA:\n\nPatients\n\nPatients will be excluded for any of the following:\n\n1. The presence of certain types of acquired abnormalities of immunity due to:\n\n   * HIV\n   * Cancer chemotherapeutic agent(s)\n   * An underlying malignancy could be grounds for possible exclusion of a patient if, in the opinion of the investigator, the underlying disease predisposed the patient to the infection\n   * Monoclonal antibody therapy directed against a patient s immune system\n2. Any condition that in the opinion of the investigator may interfere with the evaluation of a co-existing abnormality of immunity that is the subject of study under this protocol. For example, we may exclude patients with Cushing s disease that have very high cortisol levels at the time of diagnosis of their cryptococcosis.\n\nGenetic Relatives of Patients\n\nGenetic relatives will be excluded for the following:\n\n-Any condition that in the opinion of the investigator may interfere with evaluation of an immune system abnormality that is the subject of study under this protocol.\n\nHealthy Volunteers\n\nHealthy volunteers will be excluded for any of the following:\n\n1. HIV or viral hepatitis (B or C).\n2. History of recurrent or severe infections.\n3. History of intravenous drug use.\n4. History of engaging in high-risk activities for exposure to HIV.\n5. Receiving chemotherapeutic agent(s), immunosuppressants or have underlying malignancy.\n6. Pregnancy.\n7. Have history of heart, lung, kidney disease, or bleeding disorders.\n8. Any condition that in the opinion of the investigator may interfere with evaluation of an immune system abnormality that is the subject of study under this protocol.",true,"ALL","18 Years","99 Years",{"count":21,"type":22},800,"ESTIMATED","OBSERVATIONAL","The protocol will be carried out in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) and the following United States Code of Federal Regulations (CFR) applicable to clinical studies: 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and\u002For 21 CFR Part 812.\n\nNIH-funded investigators and study site staff who are responsible for the conduct, management, or oversight of NIH-funded studies have completed Human Subjects Protection and ICH GCP Training.\n\nThe protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the Institutional Review Board (IRB) for review and approval. Approval of both the protocol and the consent form must be obtained before any participant is enrolled. Any amendment to the protocol will require review and approval by the IRB before the changes are implemented to the study. In addition, all changes to the consent form will be approved by the IRB; an IRB determination will be made regarding whether a new consent needs to be obtained from participants who provided consent, using a previously approved consent form.",[26,27,28,29,30],"Cryptococcal Infection","Cryptococcal Pneumonia","Pulmonary Cryptococcosis","Cryptococcal Meningitis","Cryptococcosis",[32,33,34,35],"Natural History","Cryptococcus","Cryptococcus Neoformans","Cryptococcus gattii","RECRUITING","2026-08-06",{"date":39,"type":40},"2026-08-07","ACTUAL",{"date":42,"type":40},"1993-04-01",{"name":44,"class":45},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":46},"100650292","phase-3-optimizing-care-for-cryptococcal-antigenemia-evaluation-of-short-course-fluconazole-and-art-timing-among-crag-persons-with-low-titers-100650292","NCT07743593","Optimizing Care for Cryptococcal Antigenemia: Evaluation of Short Course Fluconazole and ART Timing Among CrAg+ Persons With Low Titers","Inclusion Criteria:\n\n* HIV-1 infection\n* Age greater than 18 years\n* Ability and willingness to give informed consent\n* Plasma or serum cryptococcal antigen positive with titer less than 1:160\n\nExclusion Criteria:\n\n* Cannot or unlikely to attend regular clinic visits\n* History of cryptococcal infection\n* Symptomatic meningitis confirmed by cerebrospinal fluid cryptococcal antigen positivity\n* More than 10 weeks of fluconazole therapy\n* Pregnancy confirmed by urinary or serum pregnancy test\n* Current breastfeeding",{"count":54,"type":22},505,"INTERVENTIONAL",[57],"PHASE3","This randomized clinical trial will evaluate the optimal duration of fluconazole therapy and timing of antiretroviral therapy initiation among HIV-infected persons with asymptomatic cryptococcal antigenemia and low cryptococcal antigen titers in Uganda.\n\nParticipants with low-titer cryptococcal antigenemia will be followed to assess whether a shorter 10-week course of fluconazole is non-inferior to the standard 24-week fluconazole regimen for 24-week cryptococcal meningitis-free survival. Among participants eligible for antiretroviral therapy timing randomization, the study will also compare immediate antiretroviral therapy initiation with delayed initiation after 14 days to evaluate 10-week hospitalization-free survival.\n\nParticipants will be followed for up to 24 weeks, with study visits and contacts to assess survival, cryptococcal meningitis, hospitalizations, adverse events, and fluconazole adherence.",[60,61,26,29],"Cryptococcal Antigenemia","HIV-1-infection",[63,64,65,66,67,68,69,70,71,72,73,74],"Cryptococcal antigen","CrAg","Fluconazole","Fluconazole Short-course fluconazole","Low CrAg titer","Immediate ART","Advanced HIV disease","Cryptococcal meningitis-free survival","Hospitalization-free survival","Uganda","ART initiation","Antiretroviral therapy","NOT_YET_RECRUITING","2026-07-30",{"date":78,"type":40},"2026-08-04",{"date":80,"type":22},"2026-09-01",{"date":82,"type":22},"2031-08-30",{"name":84,"class":85},"University of Minnesota","OTHER"]